The Market Reports

Synopsis
The global market for Influenza Vaccine was estimated to be worth US$ 9135 million in 2024 and is forecast to a readjusted size of US$ 13500 million by 2031 with a CAGR of 5.5% during the forecast period 2025-2031.
Influenza vaccines, also known as flu shots, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. Most provide modest to high protection against influenza; however, each year this varies. Evidence in adults over 65 years old is poor. They decrease the number of missed days of work by a half day on average. Vaccinating children may protect those around them.
Market Driver:The Influenza Vaccine market is driven by the rising global awareness of flu prevention and increasing government initiatives to promote vaccination programs. Seasonal influenza poses a significant public health burden, leading to hospitalizations and fatalities, particularly among high-risk populations such as the elderly, young children, and immunocompromised individuals. Governments and health organizations, including the WHO and CDC, actively support annual flu vaccination campaigns to reduce disease transmission. Additionally, advancements in vaccine technology, such as cell-based and recombinant influenza vaccines, are improving vaccine efficacy and production efficiency, further driving market growth.
Market Challenge:Despite its importance, the Influenza Vaccine market faces challenges related to vaccine hesitancy, manufacturing constraints, and viral mutations. Public skepticism regarding vaccine safety and effectiveness, fueled by misinformation, hampers vaccination rates in some regions. Additionally, influenza viruses undergo frequent genetic mutations, requiring annual vaccine updates and posing challenges in predicting dominant strains. Manufacturing influenza vaccines is also time-sensitive, as traditional egg-based production methods have limitations in scalability and response speed during pandemics. These factors can impact supply chain stability and overall vaccine accessibility.
Global key players of Pandemic Influenza Vaccine include Sanofi, CSL and GSK, etc. The top five players hold a share about 80%. North America is the largest market, has a share about 50%.
This report aims to provide a comprehensive presentation of the global market for Influenza Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Influenza Vaccine by region & country, by Type, and by Application.
The Influenza Vaccine market size, estimations, and forecasts are provided in terms of sales volume (M Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Influenza Vaccine.
Market Segmentation
By Company
Sanofi
CSL
GSK
Viatris
AstraZeneca
Hualan Bio
Changchun Institute of Biological
Sinovac
BCHT
Jiangsu GDK
KM Biologics
Segment by Type
Trivalent Influenza Vaccine
Quadrivalent Influenza Vaccine
Segment by Application
6 Months to 3 Years
> 3 Years
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Influenza Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Influenza Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Influenza Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index